دورية أكاديمية
أعرض في EDS

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.

التفاصيل البيبلوغرافية
العنوان: Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.
المؤلفون: Buschow SI; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Gastroenterology and Hepatology, Erasmus University Medical Center (Erasmus MC), Rotterdam, The Netherlands., Ramazzotti M; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy., Reinieren-Beeren IMJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Heinzerling LM; Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany., Westdorp H; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Stefanini I; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy., Beltrame L; Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy., Hato SV; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Ellebaek E; CCIT, Center for Cancer Immune Therapy, Department of Hematology and Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Gross S; Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany., Nguyen VA; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria., Weinlich G; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria., Ragoussis J; Genomics Group, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.; Current address: McGill University and Genome Quebec Innovation Centre, McGill University, Quebec, Canada., Baban D; Genomics Group, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Schuler-Thurner B; Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany., Svane IM; CCIT, Center for Cancer Immune Therapy, Department of Hematology and Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Romani N; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria., Austyn JM; Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK., De Vries IJM; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Schuler G; Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany., Cavalieri D; Department of Biology, University of Florence, Firenze, Italy., Figdor CG; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
المصدر: Oncotarget [Oncotarget] 2017 Jun 27; Vol. 8 (40), pp. 67439-67456. Date of Electronic Publication: 2017 Jun 27 (Print Publication: 2017).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Albany, N.Y. : Impact Journals
مستخلص: Immunotherapy for metastatic melanoma offers great promise but, to date, only a subset of patients have responded. There is an urgent need to identify ways of allocating patients to the most beneficial therapy, to increase survival and decrease therapy-associated morbidity and costs. Blood-based biomarkers are of particular interest because of their straightforward implementation in routine clinical care. We sought to identify markers for dendritic cell (DC) vaccine-based immunotherapy against metastatic melanoma through gene expression analysis of peripheral blood mononuclear cells. A large-scale microarray analysis of 74 samples from two treatment centers, taken directly after the first round of DC vaccination, was performed. We found that phosphatidylethanolamine binding protein 1 ( PEBP1) /Raf Kinase inhibitory protein (RKIP) expression can be used to identify a significant proportion of patients who performed poorly after DC vaccination. This result was validated by q-PCR analysis on blood samples from a second cohort of 95 patients treated with DC vaccination in four different centers. We conclude that low PEBP1 expression correlates with poor overall survival after DC vaccination. Intriguingly, this was only the case for expression of PEBP1 after, but not prior to, DC vaccination. Moreover, the change in PEBP1 expression upon vaccination correlated well with survival. Further analyses revealed that PEBP1 expression positively correlated with genes involved in T cell responses but inversely correlated with genes associated with myeloid cells and aberrant inflammation including STAT3, NOTCH1 , and MAPK1 . Concordantly, PEBP1 inversely correlated with the myeloid/lymphoid-ratio and was suppressed in patients suffering from chronic inflammatory disease.
Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest
References: Cell. 2015 Apr 9;161(2):205-14. (PMID: 25860605)
Cell Oncol (Dordr). 2014 Feb;37(1):9-15. (PMID: 24249155)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
J Transl Med. 2015 Jan 16;13:9. (PMID: 25592374)
Cancer Immunol Immunother. 2011 Feb;60(2):249-60. (PMID: 21069321)
Cytotherapy. 2010 Oct;12(6):721-34. (PMID: 20429791)
Scand J Immunol. 2004 Jun;59(6):566-73. (PMID: 15182252)
Clin Cancer Res. 2013 Oct 1;19(19):5300-9. (PMID: 24089443)
J Clin Oncol. 1999 Jun;17(6):1891-6. (PMID: 10561230)
Mol Cell Biol. 2001 Nov;21(21):7207-17. (PMID: 11585904)
Cancer Lett. 2014 Apr 28;346(1):24-33. (PMID: 24368189)
Nat Rev Cancer. 2016 May;16(5):275-87. (PMID: 27079802)
Int J Cancer. 2015 May 15;136(10 ):2352-60. (PMID: 25353097)
Front Oncol. 2015 Jul 13;5:152. (PMID: 26217587)
Bioinformatics. 2009 Nov 1;25(21):2855-6. (PMID: 19706745)
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034. (PMID: 12184808)
Nat Immunol. 2014 Feb;15(2):195-204. (PMID: 24336226)
Crit Rev Oncog. 2014;19(6):497-504. (PMID: 25597359)
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52. (PMID: 25352553)
Cancer Res. 2013 Jan 1;73(1):19-29. (PMID: 23087058)
Clin Cancer Res. 2014 Mar 15;20(6):1601-9. (PMID: 24323899)
PLoS One. 2014 Aug 19;9(8):e103883. (PMID: 25137181)
Lung Cancer. 2014 Nov;86(2):158-63. (PMID: 25263855)
J Cell Physiol. 2013 Aug;228(8):1688-702. (PMID: 23359513)
J Exp Med. 1999 Dec 6;190(11):1669-78. (PMID: 10587357)
Cancer Immunol Immunother. 2012 Oct;61(10):1791-804. (PMID: 22426890)
Inflammation. 2012 Apr;35(2):474-83. (PMID: 21556737)
Clin Cancer Res. 2016 Apr 15;22(8):1897-906. (PMID: 27084743)
Nat Commun. 2016 Jul 06;7:12150. (PMID: 27381735)
J Clin Oncol. 2005 Aug 20;23(24):5779-87. (PMID: 16110035)
Nat Genet. 2003 Jul;34(3):267-73. (PMID: 12808457)
Oncotarget. 2015 Jun 30;6(18):16422-36. (PMID: 25915430)
Cancer Res. 2012 Dec 1;72(23):6102-10. (PMID: 23010076)
Cancer Res. 2004 Aug 1;64(15):5186-92. (PMID: 15289323)
Drug Des Devel Ther. 2011;5:489-95. (PMID: 22267918)
Oncoimmunology. 2016 Apr 29;5(6):e1158901. (PMID: 27471626)
Cancer Res. 2012 Dec 1;72(23):6217-26. (PMID: 23066033)
Front Immunol. 2015 Oct 12;6:523. (PMID: 26528286)
Ann Oncol. 2014 Oct;25(10 ):1959-65. (PMID: 25185240)
Oncotarget. 2016 Jul 5;7(27):42698-42715. (PMID: 27029037)
Oncoimmunology. 2016 Jun 27;5(7):e1196312. (PMID: 27622051)
Clin Cancer Res. 2015 Dec 15;21(24):5453-9. (PMID: 26289067)
Cancer J. 2010 Jul-Aug;16(4):399-403. (PMID: 20693853)
Biotechniques. 2004 Jul;37(1):112-4, 116, 118-9. (PMID: 15283208)
F1000Res. 2014 Oct 20;3:246. (PMID: 25949802)
Sci Transl Med. 2016 Apr 13;8(334):334ra52. (PMID: 27075626)
Expert Opin Biol Ther. 2006 Jul;6(7):671-84. (PMID: 16805707)
Cancer Immunol Immunother. 2013 Nov;62(11):1711-22. (PMID: 24072401)
Bioinformatics. 2008 Jul 1;24(13):1547-8. (PMID: 18467348)
J Clin Oncol. 2009 Dec 20;27(36):6199-206. (PMID: 19917835)
Clin Cancer Res. 2016 Oct 1;22(19):4848-4858. (PMID: 27169993)
Cancer Immunol Immunother. 2008 Oct;57(10):1559-68. (PMID: 18618110)
Clin Cancer Res. 2016 Nov 15;22(22):5487-5496. (PMID: 27185375)
Br J Cancer. 2013 Nov 26;109(11):2833-41. (PMID: 24196789)
Nature. 1999 Sep 9;401(6749):173-7. (PMID: 10490027)
Cancer Immunol Immunother. 2012 Jun;61(6):827-38. (PMID: 22080405)
Clin Cancer Res. 2010 Oct 15;16(20):5067-78. (PMID: 20736326)
Expert Rev Vaccines. 2010 Jun;9(6):555-65. (PMID: 20518712)
Biochim Biophys Acta. 2014 Aug;1846(1):55-65. (PMID: 24727385)
N Engl J Med. 2015 Sep 24;373(13):1270-1. (PMID: 26398076)
Cancer Sci. 2016 Oct;107(10 ):1373-1379. (PMID: 27486853)
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21. (PMID: 11309499)
Clin Cancer Res. 2012 Oct 1;18(19):5460-70. (PMID: 22896657)
J Immunol. 2013 Jul 15;191(2):708-16. (PMID: 23761631)
J Immunol. 2000 Sep 15;165(6):3492-6. (PMID: 10975870)
Clin Cancer Res. 2008 May 15;14(10):2994-3001. (PMID: 18483365)
Int J Cancer. 2013 Jan 15;132(2):385-400. (PMID: 22532371)
J Clin Oncol. 2013 Jul 1;31(19):2388-95. (PMID: 23715562)
Oncotarget. 2016 Jan 26;7(4):4760-9. (PMID: 26716894)
فهرسة مساهمة: Keywords: PEBP1; dendritic cell vaccination; immune suppression; immunotherapy; melanoma
تواريخ الأحداث: Date Created: 20171006 Latest Revision: 20191120
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC5620184
DOI: 10.18632/oncotarget.18698
PMID: 28978044
قاعدة البيانات: MEDLINE
الوصف
تدمد:1949-2553
DOI:10.18632/oncotarget.18698